Cyclosporin A (CyA) in primary Sjögren's syndrome: a double blind study.
AUTOR(ES)
Drosos, A A
RESUMO
The efficacy and toxicity of cyclosporin A (CyA) were studied in a blind fashion in 20 patients with primary Sjögren's syndrome (pSS). The dose of CyA or placebo was 5 mg/kg of body weight daily. Among the 20 patients, 10 received CyA and 10 placebo. The two groups were matched for age, sex, and disease duration. Patients treated with CyA improved in subjective xerostomia in comparison with patients treated with placebo. Subjective xerophthalmia and recurrent parotid gland enlargement did not differ in the two groups. No change in Schirmer's test and stimulated parotid flow rate was observed in either group. In contrast, the histopathological lesion of patients treated with CyA remained unchanged in most of the patients, while in the placebo treated group the lesion deteriorated. Laboratory parameters did not change before or after treatment in either group. The only clinical side effect observed in the CyA treated group was hypertrichosis.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1001978Documentos Relacionados
- Effect of cyclosporin A (CyA) on the immunopathological lesion of the labial minor salivary glands from patients with Sjögren's syndrome.
- Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial.
- Lung function in primary Sjögren's syndrome: a cross sectional and longitudinal study.
- Renal Involvement in Primary Sjögren's Syndrome: A Clinicopathologic Study
- Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study
